Méndez-Sánchez N

Language: English
References: 7
Page: 4-5
PDF size: 117.64 Kb.

Text Extraction

Unzueta A, et al. Hepatitis E virus serum antibodies and RNA prevalence in patients evaluated for heart and kidney transplantation

Unzueta A, et al. In the present study authors evaluated serum from heart and kidney transplant candidates. They found 11.4% (15/132) prevalence of anti-HEV IgG for heart transplant and 8.5% (17/201) for kidney transplant candidates, with an overall seroprevalence of 9.6% (32/ 333). None of the patients tested positive for HEV RNA in the serum. On multivariable analysis, age older than 60 years was associated with HEV infection (adjusted odds ratio, 3.34; 95% CI, 1.54-7.24; P = 0.002). Authors concluded that there was no evidence of acute HEV infection in those pre-transplant population and that older age seems to be associated with positive anti-HEV IgG.

REFERENCES

1. Wedemeyer H, Pischke S, Manns MP. Pathogenesis and treatment of hepatitis E virus infection. Gastroenterology 2012; 142: e1381.

2. Fishman JA, Greenwald MA, Grossi PA. Transmission of infection with human allografts: essential considerations in donor screening. Clin Infect Dis 2012; 55: 720-7.

3. Motola-Kuba D, Zamora-Valdés D, Uribe M, Méndez-Sánchez N. Hepatocellular carcinoma. An overview. Ann Hepatol 2006; 5: 16-24.

4. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005; 25: 181-200.

5. Wang JH, Wang CC, Hung CH, Chen CL, Lu SN. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol 2012; 56: 412-8.

6. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.

7. Giorgio A, Di Sarno A, De Stefano G, Scognamiglio U, Farella N, Mariniello A, Esposito V, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Res 2011; 31: 2291-5.